Next Article in Journal
Public Health Care Financing and the Costs of Cancer Care: A Cross-National Analysis
Next Article in Special Issue
Electron Nuclear Dynamics Simulations of Proton Cancer Therapy Reactions: Water Radiolysis and Proton- and Electron-Induced DNA Damage in Computational Prototypes
Previous Article in Journal
YAP/TAZ Activation as a Target for Treating Metastatic Cancer
Previous Article in Special Issue
Proton Partial Breast Irradiation: Detailed Description of Acute Clinico-Radiologic Effects
Open AccessArticle

Proton Beam Therapy Alone for Intermediate- or High-Risk Prostate Cancer: An Institutional Prospective Cohort Study

1
Medipolis Proton Therapy and Research Center, 4233 Higashikata, Ibusuki, Kagoshima 8910304, Japan
2
Department of Radiology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908520, Japan
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(4), 116; https://doi.org/10.3390/cancers10040116
Received: 30 January 2018 / Revised: 5 April 2018 / Accepted: 6 April 2018 / Published: 10 April 2018
(This article belongs to the Special Issue Proton and Carbon Ion Therapy)
The role of proton beam therapy (PBT) as monotherapy for localized prostate cancer (PCa) remains unclear. The purpose of this study was to evaluate the efficacy and adverse events of PBT alone for these patients. Between January 2011 and July 2014, 218 patients with intermediate- and high-risk PCa who declined androgen deprivation therapy (ADT) were enrolled to the study and were treated with PBT following one of the following protocols: 74 Gray (GyE) with 37 fractions (fr) (74 GyE/37 fr), 78 GyE/39 fr, and 70 GyE/28 fr. The 5-year progression-free survival rate in the intermediate- and high-risk groups was 97% and 83%, respectively (p = 0.002). The rate of grade 2 or higher late gastrointestinal toxicity was 3.9%, and a significant increased incidence was noted in those who received the 78 GyE/39 fr protocol (p < 0.05). Grade 2 or higher acute and late genitourinary toxicities were observed in 23.5% and 3.4% of patients, respectively. Our results indicated that PBT monotherapy can be a beneficial treatment for localized PCa. Furthermore, it can preserve the quality of life of these patients. We believe that this study provides crucial hypotheses for further study and for establishing new treatment strategies. View Full-Text
Keywords: prostate cancer; proton beam therapy; efficacy; adverse events; quality of life; sexual function; medical expenses prostate cancer; proton beam therapy; efficacy; adverse events; quality of life; sexual function; medical expenses
Show Figures

Figure 1

MDPI and ACS Style

Arimura, T.; Yoshiura, T.; Matsukawa, K.; Kondo, N.; Kitano, I.; Ogino, T. Proton Beam Therapy Alone for Intermediate- or High-Risk Prostate Cancer: An Institutional Prospective Cohort Study. Cancers 2018, 10, 116.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop